1,116 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
PFE Pfizer, Inc. $43.01 $252.13B N/A
Article Searches
Pfizer Gains European Approval for Amyloidosis Drug Vyndaqel https://www.fool.com/investing/2020/02/18/pfizer-eu-approval-amyloidosis-drug-vyndaqel.aspx?source=iedfolrf0000001 Feb 18, 2020 - Sales of the treatment got off to a good start in the U.S., and Europe could follow suit.
White House Claims Other Countries Are "Free-Riding" on U.S. Drug Development https://www.fool.com/investing/2020/02/13/white-house-claims-other-countries-are-free-riding.aspx?source=iedfolrf0000001 Feb 13, 2020 - It's gotten worse over the last 15 years.
Deciphera's NDA for GIST Drug Gets Priority Review From FDA http://www.zacks.com/stock/news/763964/decipheras-nda-for-gist-drug-gets-priority-review-from-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-763964 Feb 13, 2020 - The FDA accepts Deciphera's (DCPH) NDA for ripretinib and grants a priority review to the same for the treatment of advanced gastrointestinal stromal tumors.
Merck's Keytruda Meets PFS Endpoint in Breast Cancer Study http://www.zacks.com/stock/news/763946/mercks-keytruda-meets-pfs-endpoint-in-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-763946 Feb 13, 2020 - Merck's (MRK) immuno-oncology drug, Keytruda, significantly improves progression free survival as first-line treatment for metastatic triple-negative breast cancer patients in a pivotal study.
Blueprint Medicines' NDA for Avapritinib Gets Extended Review http://www.zacks.com/stock/news/754515/blueprint-medicines-nda-for-avapritinib-gets-extended-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-754515 Feb 07, 2020 - FDA extends review period for Blueprint Medicines' (BPMC) NDA seeking accelerated approval for avapritinib in fourth-line gastrointestinal stromal tumors by three months.
Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates http://www.zacks.com/stock/news/753057/bristol-myers-bmy-q4-earnings-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-753057 Feb 06, 2020 - Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat http://www.zacks.com/stock/news/750701/novo-nordisk-nvo-q4-earnings-match-estimates-revenues-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-750701 Feb 05, 2020 - Novo Nordisk (NVO) posts in-line earnings, while revenues beat estimates in the fourth quarter of 2019.
Merck's Recarbrio Gets FDA Priority Review for New Indication http://www.zacks.com/stock/news/748727/mercks-recarbrio-gets-fda-priority-review-for-new-indication?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-748727 Feb 04, 2020 - The FDA accepts Merck's (MRK) sNDA for antibacterial injection Recarbrio and grants priority review.
3 Dividend-Paying Stocks for Investors to Buy to Fight Off Market Uncertainty http://www.zacks.com/stock/news/747608/3-dividend-paying-stocks-for-investors-to-buy-to-fight-off-market-uncertainty?cid=CS-ZC-FT-stocks_in_the_news|major_headlines-747608 Feb 03, 2020 - Check out these three dividend-paying stocks that investors might want to buy to help combat coronavirus-based market pullback fears...
Q4 Earnings Scorecard and Analyst Reports for Amazon, Pfizer & Others http://www.zacks.com/research-daily/746712/q4-earnings-scorecard-and-analyst-reports-for-amazon-pfizer-others?cid=CS-ZC-FT-research_daily-746712 Feb 03, 2020 - Q4 Earnings Scorecard and Analyst Reports for Amazon, Pfizer & Others

Pages: 123456...112

Page 1>